LEO Pharma acquires worldwide rights to dersimelagon in deal worth up to $435 million
- nuaxia
- 2 days ago
- 2 min read
The agreement adds a late-stage oral therapy for rare genetic photodermatoses to LEO Pharma's dermatology pipeline while expanding its focus on rare skin diseases.
LEO Pharma has agreed to acquire the worldwide rights to dersimelagon from Tanabe Pharma for up to $435 million in upfront and near-term milestone payments, together with potential downstream milestones and tiered royalties.
The acquisition gives LEO Pharma a Phase III-complete investigational oral therapy for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), strengthening its rare dermatology pipeline ahead of a potential US launch, subject to regulatory approval.
Field | Content |
Alert Type | Deal |
Companies | LEO Pharma; Tanabe Pharma Corporation |
Deal Type | Asset acquisition / global licensing rights acquisition |
Asset or Company | Worldwide rights to dersimelagon (MT-7117) |
Therapy Area(s) | Rare dermatology; Rare genetic skin diseases |
Technology or Modality | Oral small-molecule melanocortin 1 receptor (MC1R) agonist |
Deal Value | Up to $435 million in upfront and near-term milestone payments, together with potential downstream development and commercial milestones and tiered royalties on net sales. The $435 million does not represent guaranteed consideration. (LEO Pharma) |
Development Stage | NDA under FDA review following completed Phase III development |
Geography | Worldwide |
What Happened | On 18 August 2026, LEO Pharma announced an agreement to acquire the worldwide rights to dersimelagon from Tanabe Pharma. Dersimelagon is a once-daily oral MC1R agonist being developed for EPP and XLP and has completed Phase III development, with a New Drug Application submitted to the FDA in June 2026. The transaction remains subject to customary closing conditions, including regulatory approvals. (LEO Pharma) |
Why It Matters | The acquisition adds a late-stage rare disease programme to LEO Pharma's dermatology portfolio and supports its strategy of expanding through targeted acquisitions and partnerships. If approved, dersimelagon could become the first oral therapy for EPP and XLP, although regulatory approval has not yet been granted. (LEO Pharma) |
Supporting Context | EPP and XLP are rare inherited disorders characterised by severe, painful phototoxic reactions following exposure to sunlight. Phase III data showed statistically significant improvements in sunlight tolerance, and the programme is currently under FDA review. (LEO Pharma) |
Strategic Rationale | LEO Pharma gains a late-stage asset that complements its growing rare dermatology portfolio and leverages its established global commercial infrastructure in dermatology. Tanabe Pharma monetises the programme while remaining eligible for future milestone payments and royalties. (LEO Pharma) |
Potential Impact | If approved, dersimelagon could broaden LEO Pharma's rare disease portfolio with a novel oral treatment option for patients with EPP and XLP. The programme's clinical and commercial impact will depend on FDA review, successful transaction completion and subsequent market uptake. (LEO Pharma) |
Key Takeaway | LEO Pharma is investing up to $435 million to strengthen its rare dermatology pipeline with a Phase III-complete oral therapy approaching potential regulatory approval. (LEO Pharma) |
What to Watch | Completion of the transaction, the FDA's review of the pending NDA, potential regulatory decisions in additional markets and LEO Pharma's commercial launch plans if the therapy is approved. (LEO Pharma) |
Primary Source | |
Relevant Date | 18 August 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments